日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Immune profile diversity is achieved with synthetic TLR4 agonists combined with the RG1-VLP vaccine in mice.

在小鼠中,将合成的 TLR4 激动剂与 RG1-VLP 疫苗结合使用,可以实现免疫谱多样性

Matthews Rebecca L, Khan Nazneen, Beckman Bradley, Sharma Simran, Dietz Zackary, Picking William D, Izmirlian Grant, Sanders Chelsea, Stocks Stacy M, Difilippantonio Simone, Kirnbauer Reinhard, Roden Richard B, Pinto Ligia A, Shoemaker Robert H, Ernst Robert K, Marshall Jason D

A lipid A-based TLR4 mimetic effectively adjuvants a Yersinia pestis rF-V1 subunit vaccine in a murine challenge model

在小鼠攻毒模型中,基于脂质A的TLR4模拟物可有效佐剂鼠疫耶尔森菌rF-V1亚单位疫苗。

Gregg, Kelsey A; Harberts, Erin; Gardner, Francesca M; Pelletier, Mark R; Cayatte, Corinne; Yu, Li; McCarthy, Michael P; Marshall, Jason D; Ernst, Robert K

Rationally Designed TLR4 Ligands for Vaccine Adjuvant Discovery

合理设计的TLR4配体用于疫苗佐剂的发现

Gregg, Kelsey A; Harberts, Erin; Gardner, Francesca M; Pelletier, Mark R; Cayatte, Corinne; Yu, Li; McCarthy, Michael P; Marshall, Jason D; Ernst, Robert K

Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir

添加稳定乳剂和 Toll 样受体 9 激动剂佐剂的预防性单纯疱疹病毒 2 型 (HSV-2) 疫苗可诱导强大的 HSV-2 特异性细胞介导免疫反应,预防症状性疾病,并减少潜伏病毒库。

Hensel, Michael T; Marshall, Jason D; Dorwart, Michael R; Heeke, Darren S; Rao, Eileen; Tummala, Padmaja; Yu, Li; Cohen, Gary H; Eisenberg, Roselyn J; Sloan, Derek D